Evidence map›Paper›PMID 39980346›Full record

Trial reportEuropean journal of endocrinology2025

Sex steroid hormones and subclinical atherosclerosis progression in postmenopausal women.

Irene J Chen, Frank Z Stanczyk, Intira Sriprasert, Roksana Karim, Donna Shoupe, Naoko Kono, Howard N Hodis, Wendy J Mack

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00114517 (Biologic Response of Menopausal Women to 17B-Estradiol), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00114517 phase2completednot on this map

Biologic Response of Menopausal Women to 17B-Estradiol

TypeinterventionalSponsorUniversity of Southern CaliforniaRan2004 to 2013Enrolled643ConditionsAtherosclerosisArms17B-estradiol, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Irene J ChenDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, United States.ORCID 0000-0001-5470-655X
Frank Z StanczykDepartment of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States.
Intira SriprasertDepartment of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States.ORCID 0000-0001-5367-762X
Roksana KarimDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, United States.
Donna ShoupeDepartment of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States.
Naoko KonoDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, United States.
Howard N HodisDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, United States.
Wendy J MackDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, United States.

Funding

National Institute on Aging, National Institutes of Health R01-AG024154
6 · The paper itself

Abstract

objectiveThe Early versus Late Intervention Trial with Estradiol demonstrated that hormone therapy (HT) reduces subclinical atherosclerosis progression in healthy postmenopausal women who initiated HT in proximity to menopause (<6 years) but not in those distant from menopause (≥10 years). This analysis explores the role of serum sex steroid hormones and sex hormone-binding globulin (SHBG) in atherosclerosis progression, examining differences based on time since menopause.

designPost-trial analysis.

methodsThe study included 535 healthy postmenopausal women; nearly half received HT. Serum levels of estradiol, estrone, testosterone, and SHBG were measured at baseline, 12 months, and 36 months. Carotid artery intima-media thickness (CIMT) was assessed every 6 months. Mixed-effects linear models evaluated the relationship between sex steroid hormones, SHBG, and CIMT progression, with time since menopause included as an interaction term, adjusting for age, hysterectomy, baseline CIMT, systolic blood pressure, and body mass index.

resultsLate postmenopausal women were older with higher baseline CIMT. Associations between estradiol, estrone, and SHBG levels with CIMT progression differed significantly by time since menopause (interaction P < .01). In early postmenopause, CIMT progression was significantly inversely associated with SHBG (P = .024) and nonsignificantly inversely with estradiol and estrone. In late postmenopause, CIMT progression was significantly positively associated with estradiol (P = .005), estrone (P < .001), and SHBG (P = .037).

conclusionsSerum sex steroid hormones and SHBG relate differently to CIMT progression based on time since menopause. Estradiol, estrone, and SHBG levels show opposite associations with CIMT progression in early versus late postmenopause, highlighting the importance of HT timing in cardiovascular disease. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT00114517.

Indexed as

AtherosclerosisGonadal Steroid HormonesPostmenopauseSex Hormone-Binding GlobulinAgedCarotid Intima-Media ThicknessDisease ProgressionEstradiolEstrogen Replacement TherapyEstroneFemaleHumansMiddle AgedTestosteroneEstradiolEstroneGonadal Steroid HormonesSex Hormone-Binding GlobulinTestosteronepostmenopausal womensex steroid hormonessubclinical atherosclerosis progressiontiming hypothesisvascular healthwomen's health

Identifiers

PMID39980346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.